Pfizer Inc. ventured out of its comfort zone last week, stepping away from the world of primary care blockbusters like Lipitor (atorvastatin), Celebrex (celecoxib) and Viagra (sildenafil) and into the historically biotech territory of ultra-orphan diseases. Read More
